Morning Read: AstraZeneca deal for psoriasis drug valued at up to $445M
AstraZeneca entered into a licensing agreement, valued at up to $445 million, for its experimental psoriasis drug.
AstraZeneca entered into a licensing agreement, valued at up to $445 million, for its experimental psoriasis drug.